Product research

Research results on biocomposite products presented at AAOS – Med-Tech Innovation

Biocomposites, an international medical device company that designs, manufactures and markets products for the management of infections in bone and soft tissue, announced that research results comparing the effectiveness of its Stimulan Calcium Matrix products and genex for antimicrobial potency and bacterial biofilm killing efficiency, is presented by Paul Stoodley at the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting.

Paul Stoodley, PhD. Director, Campus Microscopy and Imaging Facility (CMIF), Professor, Departments of Microbial Infection and Immunity and Orthopedics, Infectious Diseases Institute, The Ohio State University, said: “I am delighted to present this research, which shows the effectiveness of both calcium matrix products. . Stimulan and genex exhibit similar levels and durations of antimicrobial activity in vitro against pathogens common to orthopedic infections, and significantly reduce the bioburden in planktonic and biofilm phenotypes. The global increase in infections caused by antibiotic resistant bacteria has necessitated more targeted antibiotic therapy and the flexibility for surgeons managing the infection to use the antibiotics chosen at patient-specific concentration levels.

Michael Harris, CEO of Biocomposites, added: “In the context of the pandemic, Biocomposites has continued to execute its strategy of developing and delivering high quality, cost effective and essential essential products to healthcare systems and patients around the world. . We are excited to present our research results at this prestigious event and continue to demonstrate that our products can dramatically improve patient outcomes. “

Since the last AAOS annual meeting, the biocomposites have received European approval for mixing Stimulan with antibiotics: vancomycin, gentamicin and tobramycin, for use in infected bone and soft tissue, and Canadian approval. for use in the treatment of bacterial infection in the soft tissues surrounding bone, making it the first and only approved calcium matrix which may contain an antibiotic to treat bacterial infection. Biocomposites also launched the Stimulan Rapid Cure 3cc product in the United States, designed specifically for small voids in the foot and ankle, orthopedic reconstruction and trauma procedures.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *